Shares of pharmaceutical company Novo Nordisk increased by six percent on Wednesday after the firm released quarterly financial results that surpassed Wall Street projections.
The positive market reaction was driven primarily by sales of the company's oral Wegovy treatment, which significantly exceeded analyst forecasts during the period.
Following the financial performance, management raised its official outlook for the upcoming period, according to the announcement released early Wednesday.
Further updates regarding the company's financial trajectory and product performance are anticipated as the story develops.
